<DOC>
	<DOCNO>NCT00952497</DOCNO>
	<brief_summary>The objective study evaluate anti-tumor activity , safety , tolerability telatinib use combination chemotherapy ( capecitabine cisplatin ) first-line therapy subject advance gastric cancer . The primary objective ass progression free survival ( PFS ) subject receive telatinib combination chemotherapy ( capecitabine cisplatin ) . The secondary objective assess overall survival , overall response rate , safety tolerability , pharmacokinetics biomarkers .</brief_summary>
	<brief_title>A Study Telatinib Combination With Chemotherapy Subjects With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma stomach gastroesophageal junction inoperable locally advanced metastatic disease , amenable curative therapy Measurable disease : At least 1 measurable metastatic lesion irradiate ; The lesion measure accord RECIST evaluate radiologically within 28 day prior study entry ECOG performance status 0 1 study entry Adequate bone marrow , liver renal function Women childbearing potential : Negative serum pregnancy test within 7 day must agree use adequate contraception ( barrier method birth control ) prior study entry , duration study participation 28 day last study drug dose Previous chemotherapy locally advance metastatic gastric cancer : prior neoadjuvant adjuvant chemotherapy complete least 6 month prior study entry allow Previous antiangiogenic therapy : Anti VEGF VEGFR tyrosine kinase inhibitor bevacizumab , sorafenib , sunitinib , AZD2171 Previous total platinum dose &gt; 300 mg/m2 : total prior platinum dose â‰¤300 mg/m2 allow adjuvant neoadjuvant set Candidates curative therapy Clinical radiographic evidence brain metastasis Cardiac disease ; uncontrolled hypertension ; hemorrhage/bleeding event Known suspected allergy component telatinib , cisplatin capecitabine Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Unable take oral medication could affect oral intake capecitabine telatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastro-Esophageal Cancer</keyword>
	<keyword>GE-Junction</keyword>
	<keyword>Advanced Gastric Cancer</keyword>
</DOC>